Transgender, Gender-Diverse Youth Have Five Times Higher Positive Suicide Screens in ED
By Lori Solomon HealthDay Reporter
WEDNESDAY, Sept. 25, 2024 -- Transgender and gender-diverse (TGD) youth have high rates of positive suicide risk screening in the emergency department, according to a study published online Sept. 4 in Academic Pediatrics.
Amanda Burnside, Ph.D., from the Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues examined the association between gender identity and suicide risk-screening results. The analysis included electronic medical record data from youth (aged 8 to 25 years) emergency department visits with suicide risk screening performed (12,112 individuals; November 2019 to August 2022).
The researchers found that 24 percent of youth had positive screens. For the 565 emergency department visits by TGD youth, 78.1 percent had positive screens and 9.5 percent had active suicidal ideation. The adjusted odds of positive screens were 5.35 times higher among visits by TGD youth and 0.45 times lower among visits by cisgender males compared with visits by cisgender females. The adjusted odds of active suicidal ideation were 34 percent higher for cisgender males compared with visits by cisgender females.
"Opportunities may be available to improve detection, evidence-based brief interventions, and linkage to mental health services for this population," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-26 06:00
Read more
- Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
- Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
- Love Bread & Pasta? Humans' Hunger for Carbs Has Ancient Roots
- Causal Relationship Seen Between GERD and Hypertension
- 1 in 3 U.S. Teens Say They've Been Bullied
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions